^Villegas-Navarro A, Martinez-Morales M, Morales-Aguilera A (March 1986). "Pharmacokinetics of anthracene-9-carboxylic acid, a potent myotonia-inducer". Archives Internationales de Pharmacodynamie et de Thérapie. 280 (1): 5–21.
PMID3718080.
Further reading
Phillis JW, Song D, O'Regan MH (January 1998). "Tamoxifen, a chloride channel blocker, reduces glutamate and aspartate release from the ischemic cerebral cortex". Brain Research. 780 (2): 352–5.
doi:
10.1016/S0006-8993(97)01352-8.
PMID9507191.
S2CID3160962.
^Villegas-Navarro A, Martinez-Morales M, Morales-Aguilera A (March 1986). "Pharmacokinetics of anthracene-9-carboxylic acid, a potent myotonia-inducer". Archives Internationales de Pharmacodynamie et de Thérapie. 280 (1): 5–21.
PMID3718080.
Further reading
Phillis JW, Song D, O'Regan MH (January 1998). "Tamoxifen, a chloride channel blocker, reduces glutamate and aspartate release from the ischemic cerebral cortex". Brain Research. 780 (2): 352–5.
doi:
10.1016/S0006-8993(97)01352-8.
PMID9507191.
S2CID3160962.